Polar, Nidan, Bio. Falocner, Mycroft, Plex, Power, Xena, Tred, Dado, et al. If we non professional shareholders doing our DD into the science surrounding AD have uncovered as much about the subject:
"Mitochondrial dysfunction and oxidative damage are key factors involved in the pathology of many neurodegenerative diseases. Research shows that oxidative damage occurs in the brains of people with Alzheimer’s disease prior to the onset of significant plaque pathology [3]."
And the multitude of scientific abstracts about the role of the sigma-i agonists in addressing this.
Don't you think that Biogen's scientists are every bit as conversant with this information after nearly two years researching 2-73.
Then why are they putting forth a drug like BAN2401 which they describe in their own words..."As such, BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease". ......And bringing it back from the dead :
Are we looking at Corporate Momentum in $'s and reputation. Shame on you Michael Vounatsos and Dr Sandrock. Please don't ask us for a hand up out of the amyloid plaque pit.
Market Data 
Markets 
AI
